Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.63)
# 195
Out of 5,090 analysts
140
Total ratings
51.22%
Success rate
43.75%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $42 | $29.68 | +41.53% | 2 | Dec 1, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $30 → $40 | $26.32 | +51.98% | 2 | Nov 21, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $12 | $8.57 | +40.02% | 1 | Nov 19, 2025 | |
| NVAX Novavax | Reiterates: Buy | $18 → $16 | $6.79 | +135.64% | 20 | Nov 10, 2025 | |
| CYTK Cytokinetics | Reiterates: Buy | $80 → $90 | $65.60 | +37.20% | 5 | Nov 10, 2025 | |
| HROW Harrow | Reiterates: Buy | $70 → $74 | $46.88 | +57.85% | 4 | Oct 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $460 → $560 | $577.17 | -2.97% | 13 | Sep 29, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $85 → $105 | $56.93 | +84.44% | 3 | Sep 23, 2025 | |
| TGTX TG Therapeutics | Maintains: Buy | $53 → $55 | $31.01 | +77.36% | 14 | Sep 17, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $28 | $18.68 | +49.89% | 1 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.33 | +172.85% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $5.25 | +242.86% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.56 | +220.51% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $3 | $1.37 | +118.98% | 2 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 → $2 | $0.36 | +448.52% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $13.35 | +49.81% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.73 | +73.91% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $20.03 | +74.78% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $61.52 | -38.23% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $38.87 | +146.98% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.70 | -11.50% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $19.27 | +626.47% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $3.88 | +2,219.59% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.94 | +3,960.91% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $3.66 | +36.61% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $3.22 | +1,266.46% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $2.81 | +3,102.85% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.89 | +270.37% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.28 | +352,841.18% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.56 | +172,976.92% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $6.99 | +1,001.57% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.13 | +127,900.00% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $6.00 | -33.33% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $92.33 | -57.76% | 2 | Mar 18, 2020 |
Centessa Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $29.68
Upside: +41.53%
Zymeworks
Nov 21, 2025
Reiterates: Buy
Price Target: $30 → $40
Current: $26.32
Upside: +51.98%
Nuvation Bio
Nov 19, 2025
Initiates: Buy
Price Target: $12
Current: $8.57
Upside: +40.02%
Novavax
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $6.79
Upside: +135.64%
Cytokinetics
Nov 10, 2025
Reiterates: Buy
Price Target: $80 → $90
Current: $65.60
Upside: +37.20%
Harrow
Oct 1, 2025
Reiterates: Buy
Price Target: $70 → $74
Current: $46.88
Upside: +57.85%
Madrigal Pharmaceuticals
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $577.17
Upside: -2.97%
Nektar Therapeutics
Sep 23, 2025
Maintains: Buy
Price Target: $85 → $105
Current: $56.93
Upside: +84.44%
TG Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $31.01
Upside: +77.36%
Theravance Biopharma
Sep 12, 2025
Initiates: Buy
Price Target: $28
Current: $18.68
Upside: +49.89%
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $7.33
Upside: +172.85%
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $5.25
Upside: +242.86%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.56
Upside: +220.51%
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.37
Upside: +118.98%
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.36
Upside: +448.52%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $13.35
Upside: +49.81%
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.73
Upside: +73.91%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $20.03
Upside: +74.78%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $61.52
Upside: -38.23%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $38.87
Upside: +146.98%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.70
Upside: -11.50%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $19.27
Upside: +626.47%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $3.88
Upside: +2,219.59%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.94
Upside: +3,960.91%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $3.66
Upside: +36.61%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $3.22
Upside: +1,266.46%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $2.81
Upside: +3,102.85%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.89
Upside: +270.37%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.28
Upside: +352,841.18%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.56
Upside: +172,976.92%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $6.99
Upside: +1,001.57%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.13
Upside: +127,900.00%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $6.00
Upside: -33.33%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $92.33
Upside: -57.76%